ORIC
NASDAQ · Biotechnology
Oric Pharmaceuticals Inc
$13.50
+0.57 (+4.41%)
Open$12.95
Previous Close$12.93
Day High$13.50
Day Low$12.78
52W High$14.93
52W Low$7.23
Volume—
Avg Volume2.20M
Market Cap1.38B
P/E Ratio—
EPS$-1.35
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
+287.1% upside
Current
$13.50
$13.50
Target
$52.26
$52.26
$31.55
$52.26 avg
$71.26
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 151.33M | 156.80M | 123.33M |
| Net Income | -16,895,209 | -20,414,835 | -15,522,009 |
| Profit Margin | -11.2% | -13.0% | -12.6% |
| EBITDA | -22,168,918 | -26,679,727 | -20,408,682 |
| Free Cash Flow | -10,591,679 | -9,966,569 | -9,555,180 |
| Rev Growth | +7.8% | +20.1% | +4.2% |
| Debt/Equity | 0.36 | 0.45 | 0.43 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |